
|Videos|July 7, 2016
The Benefits of ASCO's TAPUR Trial
Author(s)Edward S. Kim, MD
Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses the prospective benefits of the TAPUR clinical trial, which is being conducted by ASCO.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Breakthrough Status to ICT01 Plus Venetoclax/Azacitidine in AML
2
Teclistamab Improves PFS, OS in First Relapse of Multiple Myeloma
3
Elraglusib Combo Yields Notable 24-Month Survival Benefit in Metastatic PDAC
4
Suvemcitug Plus Chemo Improves PFS and OS in Recurrent Ovarian Cancer
5
















































